Masami Kawase

Prof. Masami Kawase


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2010 in Organic Letters
Verified
Journal Article
Closed access
RSRyosuke Saijo
Ryosuke Saijo
YHYuri Hagimoto
Yuri Hagimoto
MKMasami Kawase
Masami Kawase

22 December 2007
Verified
Book Chapter
Closed access
PDF file
MKMasami Kawase
Masami Kawase
HSHiroshi Sakagami
Hiroshi Sakagami
NMNoboru Motohashi
Noboru Motohashi

9 July 2009 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
PMPéter Molnár
Péter Molnár
JDJózsef Deli
József Deli
TTToru Tanaka
Toru Tanaka
YKYoshiyuki Kann
Yoshiyuki Kann
STSatoru Tani
Satoru Tani
MKMasami Kawase
Masami Kawase

27 May 2004
Verified
Journal Article
Closed access
EYEiji Yasumoto
Eiji Yasumoto
KNKensuke Nakano
Kensuke Nakano
TNTohru Nakayachi
Tohru Nakayachi
SMSufi Reza Md Morshed
Sufi Reza Md Morshed
KHKen Hashimoto
Ken Hashimoto
Hiroshi SakagamiHiroshi Sakagami
Hiroshi Sakagami

1 July 2018 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
GWGenki Watanabe
Genki Watanabe
HSHiroshi Sekiya
Hiroshi Sekiya
ETEiji TAMAI
Eiji TAMAI
RSRyosuke Saijo
Ryosuke Saijo
HUHidemitsu Uno
Hidemitsu Uno
MKMasami Kawase
Masami Kawase
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

5 November 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
Gabriella SpenglerGabriella Spengler
Gabriella Spengler
AKAnnamária Kincses
Annamária Kincses
BRBálint Rácz
Bálint Rácz
BVBorisz Varga
Borisz Varga
GWGenki Watanabe
Genki Watanabe
MKMasami Kawase
Masami Kawase
Background/Aim: Multidrug resistance (MDR) represents a significant impediment to successful cancer treatment. In this study, novel metal [Zn(II), Cu(II), Mg(II), Ni(II), Pd(II), and Ag(I)] complexes of 2-trifluoroacetonylbenzoxazole previously synthesized and characterized by our group were tested for their MDR-reversing activity in comparison with the free ligands in L5178Y mouse T-lymphoma (MDR) cells transfected with human ATP-binding cassette sub-family B member 1 (ABCB1; P-glycoprotein) gene. Materials and Methods: Cytotoxic and antiproliferative effects of the complexes were assessed by the thiazolyl blue tetrazolium bromide (MTT) method. Modulation of ABCB1 activity was measured by rhodamine 123 accumulation assay using flow cytometry. The apoptosis-inducing activity of some complexes was also tested on the multidrug resistant L5178Y mouse T-lymphoma cells, using the annexin-V/propidium iodide assay. Results: When compared to the free ligand, a remarkable enhancement in MDR reversal and cytotoxic activity was found for the Zn(II) and Cu(II) complexes. The activity of the complexes proved to be up to 29- and 5-fold higher than that of the ligands and the ABCB1 inhibitor verapamil as positive control, respectively. The complexes possessed a remarkable potential to induce apoptosis of MDR cells. Conclusion: Our results suggest that the Zn(II) and Cu(II) complexes display significant MDR-reversing activity in a dose-dependent manner and possess strong cytotoxic activity and a remarkable potential to induce apoptosis in MDR L5178Y mouse T-lymphoma cells.